AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03045471
Drug: R-CHOP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.
Trial: NCT00777127
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
Trial: NCT02520752
Drug: INC280
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02520752
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02198326
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03407430
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the first chemotherapy cycle, the patient will receive placebo (1 capsule) BID x 4 days before pegfilgrastim 6mg SC x1; then placebo (2 capsules) BID x 7 days. During the second chemotherapy cycle, the patient will receive pregabalin in the same dosing scheme.
Trial: NCT02643017
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of same amount of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
Trial: NCT03738215
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplied in capsules
Trial: NCT02148627
Drug: LY3041658 (SC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02148627
Drug: LY3041658 (IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as slow IV infusion
Trial: NCT02148627
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as slow IV infusion
Trial: NCT02302456
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 10 mL of 0.9% sodium chloride solution within 2 minutes of birth and routine prophylactic IV injection of oxytocin
Trial: NCT01033071
Drug: Azilsartan medoxomil and chlorthalidone
RxNorm normalized name: Azilsartan Medoxomil and Chlorthalidone Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks.
Trial: NCT01033071
Drug: Azilsartan medoxomil and chlorthalidone
RxNorm normalized name: Azilsartan Medoxomil and Chlorthalidone Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to azilsartan medoxomil 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks.
Trial: NCT05332028
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patient-controlled analgesia
Trial: NCT00281671
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride infusion
Trial: NCT00684489
Drug: clinical hypertension specialist-no specific med. Any anti-hypertension meds.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: assignment to a clinical hypertension specialist. Drugs used were hypertension medications were: chlorothiazide, hydrochlorothiazide, polythiazide indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, ditiazem, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, clonidine, clonidine patch, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
Trial: NCT00684489
Drug: renin guided therapeutics-no specific med. Any anti-hypertensive med.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: renin guided therapeutics-chlorothiazide, chlorthalidone, hydrochlorothiazide, polythiazide, indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol, pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, chlonidine, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
Trial: NCT01271751
Drug: GFT505 80mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
Trial: NCT01271751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hard gelatin capsules, oral administration, 4 capsules per day before breakfast
Trial: NCT00222989
Drug: PPI
RxNorm normalized name: PPIase
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00850642
Drug: GSK2190195 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
Trial: NCT00850642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo :~2% (w/w) Ethanol, sucralose (5 mg/100 mL of oral solution) to 100 % (w/w) aqueous sodium carbonate buffer (0.010 M, pH 9-10)
Trial: NCT03166423
Drug: MU001 patches (Investigational)
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patches containing snail slime, calendula extract and propolis extract
Trial: NCT01307839
Drug: placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Research intervention: After consent has been given, either an active 5% lidocaine patch or an inactive placebo patch will be placed on the lumbar spine of the patient. Both patches appear identical to the physician. The team will then wait for the patient to request an epidural due to labor pain, a minimum of 30 minutes from patch placement and a maximum of 12 hours
Trial: NCT01418963
Drug: RO5285119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single and multiple ascending oral doses
Trial: NCT01418963
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single and multiple oral doses
Trial: NCT04751539
Drug: AND017 single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AND017 administrated as oral single-dose on Day 1 in Part A
Trial: NCT04751539
Drug: AND017 multiple dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AND017 administrated once daily from Day 1 to Day 10 in Part B
Trial: NCT04751539
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administrated once on Day 1 in Part A or daily from Day 1 to Day 10 in Part B
Trial: NCT00788749
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets 25 mg/day
Trial: NCT00788749
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets once daily
Trial: NCT00679926
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four tablets of lopinavir/ritonavir and one tablet of tenofovir given once daily
Trial: NCT00813566
Drug: 3'-deoxy-3'-[18F]fluorothymidine (FLT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brain scan with a radiolabeled imaging agent for investigating cellular proliferation of tumors
Trial: NCT00813566
Drug: [15O]-H2O
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brain scan with imaging agent to determine tumor blood flow
Trial: NCT00604123
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray twice daily for 2 weeks.
Trial: NCT02796118
Drug: ASP2151
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02796118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02963311
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Included maximally-tolerated statin therapy and/or other low density lipoprotein-cholesterol (LDL-C)-lowering therapies.
Trial: NCT04167345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to VX-814 for oral administration.
Trial: NCT01339663
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00823121
Drug: recombinant FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gonadotropin stimulation with rFSH 150 IU/day from day 2 of menstrual cycle
Trial: NCT00801359
Drug: BSSPlus solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03822832
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion
Trial: NCT05219461
Drug: Single dose of rhEGF 10mcg/ml or placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 subjects will be assigned to rhEGF 10mcg/ml eye drop and 2 subjects will be assigned to placebo
Trial: NCT05219461
Drug: Single dose of rhEGF 50mcg/ml or placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 subjects will be assigned to rhEGF 50mcg/ml eye drop and 2 subjects will be assigned to placebo
Trial: NCT05219461
Drug: Single dose of rhEGF 100mcg/ml or placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 subjects will be assigned to rhEGF 100mcg/ml eye drop and 2 subjects will be assigned to placebo
Trial: NCT05219461
Drug: Multiple dose of rhEGF 10mcg/ml or placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 subjects will be assigned to rhEGF 10mcg/ml eye drop and 2 subjects will be assigned to placebo
Trial: NCT05219461
Drug: Multiple dose of rhEGF 50mcg/ml or placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 subjects will be assigned to rhEGF 50mcg/ml eye drop and 2 subjects will be assigned to placebo
Trial: NCT05219461
Drug: Multiple dose of rhEGF 100mcg/ml or placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 subjects will be assigned to rhEGF 100mcg/ml eye drop and 2 subjects will be assigned to placebo
Trial: NCT02502773
Drug: Hydroxethyl starch
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02775474
Drug: Use of Intraoperative Intravenous Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The active control group will be given intravenous fentanyl at a fixed induction dose (6 mg / kg) and intraoperative boluses as judged necessary by the anesthesiologist
Trial: NCT00037102
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00058721
Drug: I-123-5-IA85380
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02618408
Drug: SPN-810 (18 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were randomized to receive SPN-810 low dose (18 mg) twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
Trial: NCT02618408
Drug: SPN-810 (36 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were randomized to receive SPN-810 high dose (36 mg) twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
Trial: NCT02618408
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were randomized to receive Placebo twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
Trial: NCT04650152
Drug: Tricor (fenofibrate), 145 mg, film-coated tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observational study without intervention. Fenofibrate is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.
Trial: NCT04588311
Drug: Epoetin Alfa 40000 UNT/ML
RxNorm normalized name: epoetin alfa 40000 UNT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin alfa 40,000IU 1mL pre-filled syringe given as subcutaneous injection.
Trial: NCT04870138
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alternative antibiotic treatment failure therapy: Azithromycin 2 g orally in a single dose after treatment failure with both cephalosporin and quinolone antibiotics.
Trial: NCT01691924
Drug: PBF-509
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03284099
Drug: ACEi, ARB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To take the ACEis or ARBs before bedtime instead of in the morning
Trial: NCT02195453
Drug: Placebo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000mg/m² or Pemetrexed 500mg/m²IV drip on D1 and D8,21 days for a cycle.~Cisplatin 75mg/m² IV drip for one day or two-three days total injection, 21 days for a cycle.~Placebo Capsule four granules t.i.d po.
Trial: NCT00941148
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01186601
Drug: PET tracer (BAY94-9392)
RxNorm normalized name: Pet Pectillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A radioactive dose of 300 MBq of the study drug with a total quantity of \</= 0.1 mg will be administered as slow intravenous bolus injection over up to 60 seconds
Trial: NCT00045539
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00045539
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03752463
Drug: DAOI-B group
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAOI with B dose
Trial: NCT03752463
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02500641
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium 550 mg film coated tablets. In case of colchicine intolerance patients will be treated for at least 6 months with Naproxen 550 mg BID and Omeprazole (20-40 mg once daily), if indicated to be used.
Trial: NCT02684708
Drug: cyclophosphamide, vincristine, prednisone, dacarbazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28-day chemotherapy cycle
Trial: NCT01010100
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg TID
Trial: NCT02466542
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive regular general anesthesia
Trial: NCT00543946
Drug: GAP-134
RxNorm normalized name: GAP JUNCTION ALPHA-3 PROTEIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-Hour IV infusion, SAD
Trial: NCT00569621
Drug: physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous administration
Trial: NCT01233830
Drug: AZD2423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution
Trial: NCT01233830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution
Trial: NCT00214435
Drug: once daily minimum 3-drug regimen of anti-retroviral medications
RxNorm normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01584843
Drug: GSK1358820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM injection of Botulinum Toxin Type A
Trial: NCT04751084
Drug: Buscopan 20 milligrams/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cases will be randomized to Buscopan group or Normal Saline group, injection will be given 5 minutes prior to embryo transfer
Trial: NCT03744702
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive IV ascorbic acid.
Trial: NCT00090181
Drug: MK0663, etoricoxib / Duration of Treatment: 4 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00090181
Drug: Comparator: diclofenac / Duration of Treatment: 4 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00563173
Drug: CHRONVAC-C®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA vaccine, solution for injection, i.m. administration in combination with electroporation
Trial: NCT01330927
Drug: VA106483
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral dose of placebo for 2 nights~Once daily oral dose of 0.5 mg VA106483 for 2 nights~Once daily oral dose of 1 mg VA106483 for 2 nights~Once daily oral dose of 2 mg VA106483 for 2 nights~Once daily oral dose of 4 mg VA106483 for 2 nights~Placebo: as above
Trial: NCT03834012
Drug: Beclomethasone 800 µg per day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention: Drug: Beclomethasone 800 µg HFA per day
Trial: NCT03834012
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention: Drug: placebo
Trial: NCT03834012
Drug: Beclomethasone 400 µg per day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention: Drug: Beclomethasone 400 µg HFA per day
Trial: NCT03834012
Drug: Beclomethasone 640 µg per day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention: Drug: Beclomethasone 640 µg per day
Trial: NCT01822275
Drug: Chemotherapy with Temodar.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once the patient has had surgery, patients will receive 6 weeks of radiation therapy with concurrent chemotherapy on protcol. This will be followed by a maximum of 12 cycles of adjuvent chemotherapy with Temodar.
Trial: NCT04298060
Drug: DAS181
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SD (4.5mg/day), HD (9mg/day)
Trial: NCT04298060
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 0mg/day
Trial: NCT00902031
Drug: Sennoside + Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days.~Placebo: will be taken in capsule form, similar in size, shape, and color to docusate, taken twice daily for 10 days
Trial: NCT00003592
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01826786
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to JNJ-42165279 will be orally administered once daily for 4 consecutive days.
Trial: NCT02606214
Drug: TBA-354 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03516214
Drug: EGF816
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral treatment (once daily) with the 3rd generation EGFR inhibitor EGF816.
Trial: NCT04430855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; Oral
Trial: NCT01142479
Drug: Chinese herbal medicine decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml /Qd for 6 weeks(42 days)
Trial: NCT00317252
Drug: Hold ACEI or ARB
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held at least 24 hours pre-cardiac catheterization and restarted 48-96 hours post-catheterization (after creatinine measurement)
Trial: NCT02240342
Drug: Bone marrow transplant into ovarian artery
RxNorm normalized name: Sus scrofa bone marrow preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow progenitors mobilized to peripheral blood, obtained by plasmapheresis and infused into the ovarian artery
Trial: NCT04350320
Drug: Standard therapy for COVID-19 according to the stablished hospital protocols.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard therapy for COVID-19 according to the stablished hospital protocols.